HC Wainwright & Co. Maintains Buy on Aytu BioPharma, Lowers Price Target to $6
HC Wainwright & Co. analyst Vernon Bernardino maintains Aytu BioPharma (NASDAQ:AYTU) with a Buy and lowers the price target from $11 to $6.
Aytu BioPharma Commences Late-Stage Genetic Disorder Study
Aytu BioPharma (NASDAQ: AYTU) has initiated the global Phase 3 PREVEnt clinical trial of Enzastaurin (AR101) for the treatment of patients with COL3A1-positive Vascular Ehlers-Danlos Syndrome (VEDS).
Akerna Shares Dip 53%, Here’s 78 Biggest Movers From Yesterday
Gainers
Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis.
Cantor Fitzgerald Maintains Overweight on Aytu BioPharma, Lowers Price Target to $5
Cantor Fitzgerald analyst Jennifer Kim maintains Aytu BioPharma (NASDAQ:AYTU) with a Overweight and lowers the price target from $11 to $5.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers
TC BioPharm (Holdings) (NASDAQ:TCBP) stock moved upwards by 16.8% to $1.32 during Friday's after-market session. The company's market cap stands at $37.0 million.
